Drug Profile
Research programme: hepatitis C virus NS3 and NS5 protein inhibitors - Achillion
Alternative Names: HCV NS3 polymerase inhibitors - Achillion; HCV NS5B polymerase inhibitors - Achillion; Uridine-analog nucleotide - AchillionLatest Information Update: 05 Feb 2020
Price :
$50
*
At a glance
- Originator Achillion Pharmaceuticals
- Class Nucleotides; Small molecules; Uracil nucleotides
- Mechanism of Action Hepatitis C virus NS 5 protein inhibitors; Hepatitis C virus NS3 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Hepatitis C
Most Recent Events
- 28 Jan 2020 Achillion Pharmaceuticals has been acquired by Alexion Pharmaceuticals
- 16 Jul 2016 No recent reports of development identified for research development in Hepatitis-C in USA
- 30 May 2013 Early research in Hepatitis C in USA (unspecified route)